07:00 , May 4, 2009 |  BioCentury  |  Product Development

To the Rescue

Hypoglycemia is the most common side effect of insulin treatment and can result in seizures, unconsciousness and death. Administering glucagon reverses hypoglycemia by facilitating the release of glucose into the bloodstream. Yet, according to Enject...
00:41 , Aug 11, 2007 |  BC Extra  |  Financial News

Pevion raises $29.4 million

Pevion (Bern, Switzerland) raised CHF 35 million ($29.4 million) in a series A round led by new investor BZ Bank. BB Biotech Ventures and CC Private Equity Partners, also new investors, and existing investor Bachem...
08:00 , Jan 9, 2006 |  BioCentury  |  Finance

Tier performance

Tier performance Company 12/31/04 Mcap 12/30/05 Mcap 2005 chg Top tier Genentech (DNA) $59,884 $101,750 70% Amgen (AMGN) $81,535 $97,234 19% Gilead (GILD) $15,404 $23,977 56% Genzyme (GENZ) $13,487 $18,154 35% Biogen Idec (BIIB) $22,314...
08:00 , Mar 22, 2004 |  BC Week In Review  |  Company News

Bachem, Jerini deal

Bachem will provide cGMP manufacturing for Jerini's Icatibant for clinical trials. Icatibant ( JE049 ) is a selective peptidomimetic bradykinin BK2 receptor antagonist. The compound is in Phase II studies to treat acute attacks of...
08:00 , Mar 10, 2003 |  BioCentury  |  Finance

Tracking the decline

Tracking the decline Company 3/7/03 cls 3/23/01 cls % chg Affymetrix $26.92 $26.75 1% Amersham (A) $32.96 $31.52 5% Applied Biosystems $17.54 $22.90 -23% Bachem CHF50.5 CHF116.3 -57% Invitrogen $30.69 $53.47 -43% PerkinElmer $8.22 $23.89...
08:00 , Jan 22, 2002 |  BC Week In Review  |  Company News

Bachem, Berna Biotech AG deal

The companies formed Pevion Biotech Ltd. (Bern, Switzerland), as previously announced (see BioCentury, Oct. 22, 2001). Pevion develops therapeutic and prophylactic peptide vaccines for melanomas, malaria, hepatitis C and Alzheimer's disease. Bachem AG, Bubendorf, Switzerland...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Company News

Bachem other research news

Scientists published in the Proceedings of the National Academy of Sciences evidence that selective blockade of the Kv1.3 and IKCal1 potassium channels on T cells could be used to treat MS. They showed that in...
08:00 , Nov 19, 2001 |  BC Week In Review  |  Company News

Theratechnologies, Bachem deal

BANB will develop a large scale GMP-compliant peptide synthesis process to produce TH's ThGRF peptide (TH 9507), a growth hormone-releasing factor analog. BANB will transfer the process to TH's manufacturing subsidiary Peptix (Saint-Laurent, Quebec), and...
07:00 , Oct 22, 2001 |  BC Week In Review  |  Company News

Bachem, Berna Biotech AG deal

BBIN and Bachem will form a company to develop therapeutic and prophylactic peptide vaccines for melanomas, malaria, hepatitis and Alzheimer's disease. Bachem will contribute peptide manufacturing, and BBIN will provide its virosome peptide vaccine technology....
07:00 , Oct 22, 2001 |  BioCentury  |  Finance

Ebb & Flow

Trading in Genzyme (GENZ) provided for some read as to how the market weighs current EPS vs. potential future profits. GENZ's solid third quarter results and a boost in revenue projections for its Renagel phosphate...